HARROW, INC.
HROWNasdaq
$46.65
↑ +3.9%Jul 17 close · end-of-day
Price
1Y↑ +35.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.9B
P/E
—
P/S
6.5
P/B
60.5
EV/EBITDA
91.9
PEG
—
FCF Yield
0.8%
Dividend Yield
—
Revenue (TTM)
$268.7M
Net Income (TTM)
-$15.0M
Free Cash Flow (TTM)
$14.3M
Gross Margin
74.1%
Operating Margin
7.3%
Net Margin
-5.6%
ROE
-52.1%
ROIC
6.6%
Debt / Equity
10.5
Net Cash
-$205.4M
Return 1Y
+29.1%
Company profile
Harrow Health, Inc. owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases.
- CEO
- Mark L. Baum
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Headquarters
- Tennessee
- Website
- harrowinc.com
Management & directors
- Baum Mark LCHIEF EXECUTIVE OFFICER
- Boll Andrew R.PRESIDENT AND CFO
Roles derived from SEC Form 4 filings.
Earnings
HROW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$44.2M↓ -7.6%
Diluted EPS-$0.74↑ +48.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $48.9M | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Gross profit | $34.4M | $54.3M | $63.2M | $90.6M | $150.4M | $204.4M |
| Operating income | $385,000.00 | $1.6M | $1.9M | $431,000.00 | $8.8M | $30.5M |
| Net income | -$3.4M | -$18.0M | -$14.1M | -$24.4M | -$17.5M | -$5.1M |
| Diluted EPS | -$0.13 | — | -$0.51 | -$0.75 | -$0.49 | -$0.14 |
| Operating cash flow | -$1.1M | $5.1M | $1.7M | $3.8M | -$22.2M | $43.9M |
| Free cash flow | -$2.0M | $3.3M | -$892,000.00 | $2.4M | -$23.8M | $43.0M |
| Gross margin | 70.4% | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Operating margin | 0.8% | 2.2% | 2.2% | 0.3% | 4.4% | 11.2% |
| Net margin | -6.9% | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.9M | $49.3M | $66.8M | $47.8M | $63.7M | $71.6M | $89.1M | $44.2M |
| Gross profit | $36.4M | $37.2M | $52.7M | $32.3M | $47.5M | $53.9M | $70.6M | $27.0M |
| Operating income | $1.5M | $1.3M | $12.9M | -$11.2M | $11.4M | $14.7M | $15.6M | -$22.1M |
| Net income | -$6.5M | -$4.2M | $6.8M | -$17.8M | $5.0M | $1.0M | $6.6M | -$27.6M |
| Diluted EPS | -$0.18 | -$0.12 | $0.19 | -$0.50 | $0.13 | $0.03 | $0.20 | -$0.74 |
| Operating cash flow | -$2.7M | $3.0M | -$17.8M | $19.7M | -$803,000.00 | $16.6M | $8.4M | -$9.0M |
| Free cash flow | -$3.1M | $2.3M | -$18.3M | $19.5M | -$969,000.00 | $16.4M | $8.1M | -$9.2M |
| Gross margin | 74.4% | 75.6% | 78.8% | 67.5% | 74.5% | 75.3% | 79.3% | 61.2% |
| Operating margin | 3.1% | 2.7% | 19.3% | -23.5% | 17.9% | 20.6% | 17.5% | -50.0% |
| Net margin | -13.2% | -8.6% | 10.1% | -37.2% | 7.8% | 1.4% | 7.4% | -62.4% |
Company news
Jul 20, 2026
- 8h agoSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026finance.yahoo.com
- 9h agoHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meetingfinance.yahoo.com
Jul 1, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-18 | Graves Adrienne L | Buy | 1,000 | $31.07 | $31,070.00 | filing |
| 2026-05-18 | SILVERNAIL LAUREN P | Buy | 1,000 | $31.00 | $31,000.00 | filing |
| 2026-05-14 | BAUM MARK L· CHIEF EXECUTIVE OFFICER | Buy | 10,000 | $30.20 | $302,000.00 | filing |
| 2026-05-14 | BOLL ANDREW R.· PRESIDENT AND CFO | Buy | 3,500 | $29.90 | $104,650.00 | filing |
| 2026-03-04 | Opaleye Management Inc. | Sale | 134,000 | $39.67 | $5.3M | filing |
| 2026-03-04 | Opaleye Management Inc. | Sale | 4,263 | $39.67 | $169,122.16 | filing |
| 2026-03-03 | Opaleye Management Inc. | Sale | 59,000 | $39.15 | $2.3M | filing |
| 2026-03-03 | Opaleye Management Inc. | Sale | 1,309 | $39.15 | $51,250.49 | filing |
| 2026-02-27 | Opaleye Management Inc. | Sale | 5,000 | $54.18 | $270,900.00 | filing |
| 2026-01-06 | Opaleye Management Inc. | Sale | 20,000 | $53.35 | $1.1M | filing |
| 2025-12-12 | BAUM MARK L· CHIEF EXECUTIVE OFFICER | Tax withholding | 79,994 | $47.06 | $3.8M | filing |
| 2025-12-12 | BOLL ANDREW R.· PRESIDENT AND CFO | Tax withholding | 26,665 | $47.06 | $1.3M | filing |
| 2025-12-12 | BAUM MARK L· CHIEF EXECUTIVE OFFICER | Option exercise | 180,000 | $3.95 | $711,000.00 | filing |
| 2025-12-12 | BOLL ANDREW R.· PRESIDENT AND CFO | Option exercise | 60,000 | $3.95 | $237,000.00 | filing |
| 2025-07-21 | BAUM MARK L· CHIEF EXECUTIVE OFFICER | Tax withholding | 313,338 | $37.08 | $11.6M | filing |
| 2025-07-21 | BAUM MARK L· CHIEF EXECUTIVE OFFICER | Option exercise | 600,000 | $7.87 | $4.7M | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.